Arq. Bras. Oftalmol. 2024; 87 (4): 10.5935/0004-2749.2022-0035
Total: 3166
Pablo Felipe Rodrigues1,2; Bernardo Kaplan Moscovici1; Luciano Lamazales2; Marcela Mara Silva Freitas1; José Álvaro Pereira Gomes1,2; Walton Nosé1; Mauro Silveira Campos1
DOI: 10.5935/0004-2749.2022-0035
Funding: This study received no specific financial support.
Disclosure of potential conflicts of interest: José Álvaro P. Gomes – consultant and speaker: Allergan, Alcon, Genon/Thea Laboratories, Ofta Vision Health, Johnson & Johnson. The other authors have any potential conflicts of interest to disclose.
Approved by the following research ethics committee: Instituto Suel Abujamra (CAAE: 36907320.9.0000.5477).
How to cite this article:
ABO is licensed under a Creative Commons Attribution-NonComercial 4.0 Internacional.
